EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DEBIRI in Hepatic Malignancy: A Six-Patient Case Series in Indonesia

Rio Hermawan, Koesbandono, Anthony Satriajaya, Gilbert Sterling Octavius

Gastrointestinal Disorders · 03.11.2026 · 8 (4) · 75

DOI: 10.3390/gidisord8040075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastrointestinal Disorders, online erschienen am 03.11.2026. Verfasst von Rio Hermawan und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irinotecan-loaded drug-eluting bead transarterial chemoembolization (DEBIRI) has an established but evolving evidence base for colorectal liver metastases, while its use in small-cell lung cancer (SCLC) liver metastases remains poorly characterized. To the best of our knowledge, this is the first published report of DEBIRI use from Indonesia. We describe a single-center case series of patients treated for colorectal liver metastases and small-cell lung cancer liver metastases. Six patients underwent DEBIRI at a tertiary oncology center: five with colorectal liver metastases and one with SCLC liver metastases. Clinical characteristics, procedural details, imaging response, toxicity, and outcomes were retrospectively reviewed. ECOG performance status ranged from 0 to 2. Cumulative irinotecan doses ranged from 40 to 360 mg across one to three sessions. Technical success was achieved in all procedures. Among five patients with evaluable follow-up, four had documented progression between 2.6 and 7.8 months, while one remained progression-free at last follow-up at 3.7 months. Three patients with CRLM demonstrated stable disease followed by documented progression at 3.7, 5.1, and 7.8 months. The SCLC case demonstrated progressive disease approximately 3 months after DEBIRI and subsequently showed a marked metabolic response following systemic chemotherapy. DEBIRI was technically feasible across colorectal liver metastases and SCLC with liver metastases. The colorectal cases were broadly consistent with published evidence, while the SCLC case is hypothesis-generating.

Zitieren

APA

Hermawan, R., Koesbandono, Satriajaya, A., & Octavius, G. S. (2026). DEBIRI in Hepatic Malignancy: A Six-Patient Case Series in Indonesia. Gastrointestinal Disorders, 8(4), 75. https://doi.org/10.3390/gidisord8040075

Vancouver

Hermawan R, Koesbandono, Satriajaya A, Octavius GS. DEBIRI in Hepatic Malignancy: A Six-Patient Case Series in Indonesia. Gastrointestinal Disorders. 2026;8(4):75. doi:10.3390/gidisord8040075

BibTeX
@article{Hermawan2026,
  author = {Hermawan, Rio and Koesbandono and Satriajaya, Anthony and Octavius, Gilbert Sterling},
  title = {DEBIRI in Hepatic Malignancy: A Six-Patient Case Series in Indonesia},
  journal = {Gastrointestinal Disorders},
  year = {2026},
  volume = {8},
  number = {4},
  pages = {75},
  doi = {10.3390/gidisord8040075}
}
Kostenlos starten →